Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2020-02-14 4:34 pm Purchase | 13G | X4 PHARMACEUTICALS INC XFOR | RA CAPITAL MANAGEMENT L.P. | 1,648,485 9.9% | 1,648,485 (New Position) | View |
| 2020-02-14 4:07 pm Sale | 13G | X4 PHARMACEUTICALS INC XFOR | Cormorant Asset Management LP | 488,565 2.99% | -451,822 (-48.05%) | View |
| 2020-02-14 2:44 pm Sale | 13G | X4 PHARMACEUTICALS INC XFOR | EcoR1 Capital LLC | 1,015,400 6.1% | -184,600 (-15.38%) | View |
| 2020-02-13 12:51 pm Sale | 13G | X4 PHARMACEUTICALS INC XFOR | Flynn James E | 906,937 5.48% | -289,304 (-24.18%) | View |
| 2019-12-17 4:35 pm Purchase | 13G | X4 PHARMACEUTICALS INC XFOR | EcoR1 Capital LLC | 1,200,000 7.2% | 1,200,000 (New Position) | View |
| 2019-12-09 4:51 pm Purchase | 13G | X4 PHARMACEUTICALS INC XFOR | Bain Capital Life Sciences Fund L.P. | 1,648,485 11% | 1,648,485 (New Position) | View |
| 2019-12-03 10:29 am Purchase | 13G | X4 PHARMACEUTICALS INC XFOR | Flynn James E | 1,196,241 7.22% | 348,741 (+41.15%) | View |
| 2019-07-17 4:52 pm Purchase | 13D | X4 PHARMACEUTICALS INC XFOR | Polaris Venture Partners V L.P. | 311,492 2.5% | 311,492 (New Position) | View |
| 2019-05-28 4:53 pm Unchanged | 13D | X4 PHARMACEUTICALS INC XFOR | New Enterprise Associates 16 L.P. | 0 0% | 0 (Unchanged) | View |